We evaluated the pharmacokinetics and efficacy of oral mycophenolate mofetil (MMF) for treatment of refractory GVHD. In a prospective study of acute GVHD, 9 of 19 patients (47%) had a response and ...

The efficacy and toxicity of mycophenolate mofetil (MMF) are concentration-dependent, yet a standard fixed dose of 2 g/day is currently recommended for maintenance immunosuppression in adult renal ...

† One patient had MMF as an initial treatment. ‡ In the study TAC and MMF were used alone or in combination. §In total, 17 patients were initially treated with MMF and steroids. ¶ Females ...

† One patient had MMF as an initial treatment. ‡ In the study TAC and MMF were used alone or in combination. §In total, 17 patients were initially treated with MMF and steroids. ¶ Females ...

For patients with active lupus nephritis, obinutuzumab, a humanized type II anti-CD20 monoclonal antibody plus standard ...

The following is a summary of “Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis,” published in the February 2025 ...

The following is a summary of “Tacrolimus as first line therapy in a U.S. cohort of idiopathic inflammatory myopathies ...

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

In a randomized phase 2 study, the Fred Hutch team compared the effects of two drug combinations given to prevent GVHD by suppressing the immune system: sirolimus, cyclosporine and mycophenolate ...